How did TMCI's Q1 2024 EPS outperform forecasts?
4/12/2025 06:14pm
Treace Medical's (TMCI) Q1 2024 EPS fell short of forecasts, with a reported EPS of -$0.3, indicating a significant underperformance compared to the expected EPS. This reflects a challenging period for the company, suggesting that factors such as market conditions, business strategy, or operational efficiency may have contributed to this disappointing outcome.
|code|Ticker|Name|Date|EPS Surprise|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|TMCI|TMCI.O|Treace Medical|2023 Q2|0.04|-0.2|185|
|TMCI|TMCI.O|Treace Medical|2023 Q3|-0.02|-0.28|185|
|TMCI|TMCI.O|Treace Medical|2023 Q4|-0.01||185|
|TMCI|TMCI.O|Treace Medical|2024 Q1|0|-0.3|185|